Nu Skin Enterprises, Inc.

NYSE:NUS Stock Report

Mkt Cap: US$1.7b

We’ve recently updated our valuation analysis.

Nu Skin Enterprises Valuation

Is NUS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NUS?

Other financial metrics that can be useful for relative valuation.

NUS key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1x
Enterprise Value/EBITDA10x
PEG Ratio1.2x

Price to Earnings Ratio vs Peers

How does NUS's PE Ratio compare to its peers?

The above table shows the PE ratio for NUS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average13.7x
OLPX Olaplex Holdings
10.3x13.8%US$2.1b
EPC Edgewell Personal Care
21.6x18.3%US$2.1b
HLF Herbalife
4.7x16.3%US$1.2b
USNA USANA Health Sciences
18.1x0.4%US$1.2b
NUS Nu Skin Enterprises
21.7x17.6%US$1.7b

Price-To-Earnings vs Peers: NUS is expensive based on its Price-To-Earnings Ratio (21.7x) compared to the peer average (13.7x).

Price to Earnings Ratio vs Industry

How does NUS's PE Ratio compare vs other companies in the US Personal Products Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a20.8%
 n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a20.8%
 n/an/an/a
No more companies

Price-To-Earnings vs Industry: NUS is expensive based on its Price-To-Earnings Ratio (21.7x) compared to the US Personal Products industry average (21.6x)

Price to Earnings Ratio vs Fair Ratio

What is NUS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NUS PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio21.7x
Fair PE Ratio21.9x

Price-To-Earnings vs Fair Ratio: NUS is good value based on its Price-To-Earnings Ratio (21.7x) compared to the estimated Fair Price-To-Earnings Ratio (21.9x).

Share Price vs Fair Value

What is the Fair Price of NUS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: NUS ($33.62) is trading above our estimate of fair value ($23.69)

Significantly Below Fair Value: NUS is trading above our estimate of fair value.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst NUS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$33.62
US$40.25
+19.7%
4.8%US$43.00US$38.00n/a4
May ’24US$40.04
US$40.25
+0.5%
4.8%US$43.00US$38.00n/a4
Apr ’24US$39.31
US$40.25
+2.4%
4.8%US$43.00US$38.00n/a4
Mar ’24US$40.70
US$40.25
-1.1%
4.8%US$43.00US$38.00n/a4
Feb ’24US$44.28
US$38.25
-13.6%
5.0%US$40.00US$35.00n/a4
Jan ’24US$42.16
US$39.25
-6.9%
7.3%US$43.00US$35.00n/a4
Dec ’23US$40.84
US$37.75
-7.6%
9.4%US$43.00US$34.00n/a4
Nov ’23US$39.17
US$41.75
+6.6%
5.7%US$45.00US$39.00n/a4
Oct ’23US$33.37
US$47.00
+40.8%
9.4%US$52.00US$40.00n/a4
Sep ’23US$40.71
US$47.00
+15.5%
9.4%US$52.00US$40.00n/a4
Aug ’23US$44.56
US$49.20
+10.4%
8.0%US$55.00US$45.00n/a5
Jul ’23US$44.72
US$51.60
+15.4%
11.3%US$60.00US$45.00n/a5
Jun ’23US$46.78
US$51.60
+10.3%
11.3%US$60.00US$45.00US$33.625
May ’23US$42.64
US$60.80
+42.6%
11.6%US$70.00US$50.00US$40.045
Apr ’23US$48.82
US$63.50
+30.1%
13.6%US$75.00US$50.00US$39.316
Mar ’23US$45.20
US$63.50
+40.5%
13.6%US$75.00US$50.00US$40.706
Feb ’23US$51.06
US$59.00
+15.6%
14.7%US$72.00US$47.00US$44.286
Jan ’23US$50.75
US$56.50
+11.3%
15.2%US$72.00US$47.00US$42.166
Dec ’22US$43.12
US$56.50
+31.0%
15.2%US$72.00US$47.00US$40.846
Nov ’22US$40.79
US$55.50
+36.1%
17.4%US$72.00US$43.00US$39.176
Oct ’22US$41.48
US$66.33
+59.9%
7.3%US$72.00US$59.00US$33.376
Sep ’22US$51.07
US$64.00
+25.3%
6.7%US$70.00US$59.00US$40.714
Aug ’22US$53.69
US$64.00
+19.2%
5.9%US$70.00US$60.00US$44.565
Jul ’22US$56.66
US$64.00
+13.0%
5.9%US$70.00US$60.00US$44.725
Jun ’22US$60.93
US$63.20
+3.7%
4.3%US$66.00US$60.00US$46.785

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies